Company: GNMSF
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001558370-25-000846
Chunk: 119

Company: GENMAB A/S
Filing Date: 2025-02-12
Form: 20-F
Item: Item 6
Chunk 119
---
 must include at least three non-executive directors, the majority of whom must be independent, with a broad scientific and medical understanding and experience, appointed by the Board. As of the date of this Annual Report on Form 20-F, the Scientific Committee consists of members Anders Gersel Pedersen and Rolf Hoffmann and is chaired by Paolo Paoletti. The Scientific Committee provides input and advises the Board in matters relating to our research and development strategy, including reviewing our pre-clinical and clinical product pipeline in view of our overall strategy and vision. The Scientific Committee’s primary responsibilities include the following:

93

●   reviewing and discussing our pre-clinical and clinical product portfolio, including the commercial attractiveness and the ranking thereof;
----------------------------------------------------------------------------------------------------------------------------------------------

●   reviewing and discussing our research and development strategy and reviewing scientific and technological trends that we believe are of significant importance and providing strategic advice and making recommendations with respect to our ongoing research and development programs;
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   providing advice on external opportunities related to our research and development strategy and pipeline;
-------------------------------------------------------------------------------------------------------------

●   discuss and provide advice on the research and development capacity and its organization, including the product development process; and
--------------------------------------------------------------------------------------------------------------------------------------------

●   reviewing and discussing the Company’s intellectual property strategies.
----------------------------------------------------------------------------
D.   Employees
As of December 31, 2024, we had 2,682 employees; 519 in Denmark, 792 in the Netherlands, 1,074 in the U.S., 186 in Japan, and 111 in China. Of these employees, 1,886 were engaged in or supported research and development and 796 were in selling, administrative and business-related positions. Each of our employees has signed confidentiality and inventions assignment agreements or has signed employment agreements containing confidentiality and inventions assignment provisions, and none are covered by a collective bargaining agreement. We have never experienced employment-related work stoppages and consider our employee relations to be good.
E.   Share Ownership
For information regarding the share ownership of our directors and members of Executive Management, see “Item 6.B—Compensation” and “Item 7.A—Major Shareholders.”
F.   Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation 
Not applicable.